CFDE Data Portal | Search SLC38A4-AS1

	Label	Description
	SLC38A4-AS1 Gene (Entity type)	ENSG00000257261 - SLC38A4 antisense RNA 1
	GSE239844 crizotinib 6 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE168473 0 V 1 ISONIAZID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE120210 GSE120214 TBXT brachyury inhibition 4 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216988 GSE216989 decitabine 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 5 V 4 PIRFENIDONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE228106 3 V 5 PACLITAXEL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE168596 2 V 3 ADIPONECTIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE234647 1 V 3 REGORAFENIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

SLC38A4-AS1

ENSG00000257261 - SLC38A4 antisense RNA 1

GSE239844 crizotinib 6 v 9 human up

A Gene Set from LINCS

GSE168473 0 V 1 ISONIAZID HUMAN UP

A Gene Set from LINCS

GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn

A Gene Set from LINCS

GSE120210 GSE120214 TBXT brachyury inhibition 4 v 0 human dn

A Gene Set from LINCS

GSE216988 GSE216989 decitabine 0 v 1 human up

A Gene Set from LINCS

GSE226249 5 V 4 PIRFENIDONE HUMAN DN

A Gene Set from LINCS

GSE228106 3 V 5 PACLITAXEL HUMAN DN

A Gene Set from LINCS

GSE168596 2 V 3 ADIPONECTIN MOUSE DN

A Gene Set from LINCS

GSE234647 1 V 3 REGORAFENIB HUMAN UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.